Medication is the foundation of opioid treatment
Opioid use disorder is a treatable medical condition involving a problematic pattern of opioid use that causes impairment or distress. Treatment may be delivered through primary care, an opioid treatment program, an outpatient clinic, telehealth, residential care, or a hospital, depending on clinical needs and local rules. Methadone and buprenorphine can reduce illicit opioid use and support retention, while naltrexone works differently and requires complete withdrawal before starting. The best choice depends on access, previous response, health, preference, and the ability to begin safely.
Counseling can help without becoming a gate
Methadone, buprenorphine, and naltrexone are FDA-approved medications for opioid use disorder, and SAMHSA recommends offering evidence-based medication as part of care. Methadone and buprenorphine reduce opioid use and support retention, while naltrexone requires completion of opioid withdrawal before initiation. Therapy, peer support, and practical services may address trauma, relationships, housing, or daily routines. Patients should not lose life-saving medication simply because they cannot attend a particular group or because one counseling approach does not fit.
Starting care should be fast and individualized
Assessment covers current opioids, overdose history, withdrawal, other substances, medications, pain, pregnancy, infections, mental health, housing, and treatment preferences. Care may combine medication, counseling, peer support, infectious disease services, naloxone, recovery supports, and help with practical barriers. The assessment reviews last use, withdrawal, fentanyl exposure, other sedatives, pregnancy, pain, overdose, and current medicines. Buprenorphine timing and methadone dosing require clinical decisions, and follow-up should be frequent enough to adjust when cravings or withdrawal continue.
Overdose prevention remains part of treatment
Overdose risk is especially high with fentanyl exposure, mixing opioids with alcohol or benzodiazepines, or returning to use after tolerance has fallen. Patients and close contacts should know how to recognize an overdose, call 911, give naloxone, provide rescue breathing when trained, and stay until emergency help arrives. Naloxone should be available to the patient and close contacts, with clear instructions to call 911 and repeat doses when needed. Treatment gaps, incarceration, hospitalization, detoxification, or stopping medication can reduce tolerance and make a return to use especially dangerous.
Access rules differ across the three medications
Ask which medications are available, how quickly treatment can start, how dosing and follow-up work, and whether the program supports continued medication without an arbitrary end date. Also ask how it treats pain, pregnancy, psychiatric conditions, stimulant use, and missed visits without forcing unnecessary discharge. Methadone for opioid use disorder is generally provided through a certified opioid treatment program, while buprenorphine can be prescribed in office-based settings. Ask about take-home doses, pharmacy access, travel, required visits, drug testing, and the process for transferring care.
Create a continuity plan before problems occur
Seek a same-day assessment when possible and use SAMHSA's locator to identify treatment that offers the preferred medication. Obtain naloxone, avoid using alone, and make a plan for gaps in medication, release from jail or hospital, or other transitions that can raise overdose risk. Write down the prescriber, pharmacy or dosing site, after-hours contact, insurance steps, and backup provider. Discuss what happens after a missed dose, emergency admission, move, pregnancy, or lost medication so an administrative problem does not become an untreated withdrawal or overdose risk.
Duration should follow benefit and patient goals
There is no universal deadline for stopping medication for opioid use disorder, and some people benefit from long-term or indefinite treatment. A taper should be voluntary, gradual, and paired with close monitoring and a way to restart promptly if risk increases. Pressure from family, housing, court, or a program should be discussed openly with the prescriber. Stability on medication is a successful treatment outcome, not a reason to force a change.